Antithrombin III "Heparin cofactor" and "heparin cofactor II" d2-Macroglobulin, d2-Antitrypsin as thrombin inhibitors Inherited and acquired antithrombin deficiencies Effective and safe therapy.
This publication covers topics related to the biochemistry and clinical significance of the proteins displaying thrombin-inhibiting activity. Only in the past twenty-five years has the biological significance of proteins inhibiting blood coagulation been recognized. These inhibitors play a key role in the regulation of blood coagulation by controlling the activated serine proteinases. Certain proteins, the antithrombins, exert their effect upon thrombin leading to a reduction in the rate of fibrin formation. Important work has been done with thrombosis; chronic liver disease; disseminated intravascular coagulation; thromboembolic episodes during pregnancy, delivery; and oral contraceptive therapy. Substitution of purified, concentrated antithrombin III fractions has proven to be an effective and safe therapy for patients with antithrombin-III deficiencies.
This important addition to scientific literature is of value to those of hematology, thrombosis research, transfusion technology and biochemistry.
Table of Contents
The Biochemistry of Antithrombin III. Clinical Significance and Laboratory Diagnosis of Antithrombin III Deficiencies. Antithrombin III in Obstetrics and Gynecology and Neonatology. The Genetics of Antithrombin III Deficiency. Prophylactic and Therapeutic Use of Antithrombin III Concentrates. Heparin Cofactor II: Structure, Function and Clinical Importance. a1-Macroglobulin and a1-Proteinase Inhibitor.